NCT04394806

Brief Summary

This study plans to learn more about how triglyceride levels in pregnancy affect newborn fat mass. Obesity in pregnancy, in the absence of gestational diabetes, is now the most common cause of large-for-gestational-age infants and increased newborn fat mass. Previous data supports the idea that maternal triglycerides, not glucose, are the strongest predictor of both total newborn fat mass and liver fat. In this study, mothers will monitor triglyceride and glucose levels at specific points in pregnancy using point-of-care meters at home. Two weeks after birth, infants will have total fat measured by air-displacement plethysmography (PEAPOD) and liver fat measures by Magnetic Resonance Spectroscopy (MRS). The central hypothesis is that in obesity, fasting triglycerides and postprandial triglycerides will predict newborn fat mass in a free-living environment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for all trials

Timeline
14mo left

Started Mar 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Mar 2022Jul 2027

First Submitted

Initial submission to the registry

May 11, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 19, 2020

Completed
1.8 years until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

May 12, 2026

Status Verified

May 1, 2026

Enrollment Period

5.3 years

First QC Date

May 11, 2020

Last Update Submit

May 7, 2026

Conditions

Keywords

TriglyceridesGlucoseAdiposityAir displacement plethysmographyContinuous glucose monitoring

Outcome Measures

Primary Outcomes (1)

  • Newborn Fat Mass

    Newborn fat mass measured by air displacement plethysmography (PeaPod)

    7-14 days after birth

Secondary Outcomes (1)

  • Newborn Intrahepatic Fat

    7-14 days after birth

Eligibility Criteria

Age0 Years - 39 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Overweight and obese pregnant women between the ages of 20-39 years old, who are receiving care at a University of Colorado Health Facility.

You may qualify if:

  • Pregnant women less than 16 weeks gestational age
  • Between the ages of 21-39 years
  • Pre-pregnancy BMI 28-39 kg/m2

You may not qualify if:

  • Pre-gestational diabetes or prediabetes
  • History of gestational diabetes
  • History of pre-eclampsia, spontaneous pre-term delivery, or gestational hypertension \<34wks
  • Tobacco or illicit substance use
  • Chronic steroid use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado/Anschutz Medical Campus

Aurora, Colorado, 80045, United States

RECRUITING

Related Publications (1)

  • Barbour LA, Farabi SS, Friedman JE, Hirsch NM, Reece MS, Van Pelt RE, Hernandez TL. Postprandial Triglycerides Predict Newborn Fat More Strongly than Glucose in Women with Obesity in Early Pregnancy. Obesity (Silver Spring). 2018 Aug;26(8):1347-1356. doi: 10.1002/oby.22246. Epub 2018 Jun 22.

    PMID: 29931812BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum, plasma, cord blood, cord and placental tissue,

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Linda A Barbour, MD, MSPH

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR
  • Teri L Hernandez, PhD, RN

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2020

First Posted

May 19, 2020

Study Start

March 1, 2022

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

May 12, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations